Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients

被引:10
|
作者
Henriksen, Tenna Vesterman [1 ,2 ]
Reinert, Thomas [1 ,2 ]
Rasmussen, Mads Heilskov [1 ,2 ]
Demuth, Christina [1 ,2 ]
Love, Uffe Schou [3 ]
Madsen, Anders Husted [4 ]
Gotschalck, Kare Andersson [5 ]
Iversen, Lene Hjerrild [6 ]
Andersen, Claus Lindbjerg [1 ,2 ]
机构
[1] Aarhus Univ Hosp, Dept Mol Med, Palle Juul Jensens Blvd 99, DK-8200 Aarhus, Denmark
[2] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
[3] Reg Hosp Viborg, Dept Surg, Viborg, Denmark
[4] Reg Hosp Herning, Dept Surg, Herning, Denmark
[5] Reg Hosp Horsens, Dept Surg, Horsens, Denmark
[6] Aarhus Univ Hosp, Dept Surg, Aarhus, Denmark
关键词
circulating tumour DNA; colorectal cancer; liquid biopsy; residual disease; PCR;
D O I
10.1002/1878-0261.13294
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating tumour DNA (ctDNA) detection for postoperative risk stratification in cancer patients has great clinical potential. However, low ctDNA abundances complicates detection. Multitarget (MT) detection strategies have been developed to increase sensitivity. Yet, empirical evidence supporting performance gains of MT vs. single-target (ST) strategies in a postoperative setting is limited. We compared ctDNA detection in 379 paired plasma samples from 112 stage II-III colorectal cancer patients by ST digital PCR and MT sequencing of 16 patient-specific variants. The strategies exhibited good concordance (90%, Cohen's Kappa 0.79), with highly correlated ctDNA quantifications (Pearson r = 0.985). A difference was observed in ctDNA detection preoperatively (ST 72/92, MT 88/92). However, no difference was observed immediately after surgery in recurrence (ST 11/22, MT 10/22) or nonrecurrence (both 2/34) patients. In serial samples, detection was similar within recurrence (ST 13/16, MT 14/16) and nonrecurrence (ST 3/49, MT 1/49) patients. Both approaches yielded similar lead times to standard-of-care radiology (ST 4.0 months, MT 4.1 months). Our findings do not support significant performance gains of the MT strategy over the ST strategy for postoperative ctDNA detection.
引用
收藏
页码:3654 / 3665
页数:12
相关论文
共 50 条
  • [1] Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer.
    Chen, Gong
    Wang, Feng
    Peng, Jun-Jia
    Cai, San-Jun
    Ding, Ke-Feng
    Xiao, Qian
    Wang, Fu-Long
    Wu, Xiao-Jun
    Pan, Zhi-Zhong
    Ding, Pei-Rong
    Kong, Ling-Heng
    Wan, De-Sen
    Fan, Xiaojun
    Liu, Rui
    Bao, Hua
    Zhang, Junli
    Pang, Jiaohui
    Wu, Xue
    Shao, Yang
    Xu, Rui-hua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Impact of Postoperative Naples Prognostic Score to Predict Survival in Patients with Stage II-III Colorectal Cancer
    Park, Su Hyeong
    Woo, Hye Seung
    Hong, In Kyung
    Park, Eun Jung
    [J]. CANCERS, 2023, 15 (20)
  • [3] Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer
    Grancher, Adrien
    Beaussire, Ludivine
    Manfredi, Sylvain
    Le Malicot, Karine
    Dutherage, Marie
    Verdier, Vincent
    Mulot, Claire
    Bouche, Olivier
    Phelip, Jean-Marc
    Levache, Charles-Briac
    Deguiral, Philippe
    Coutant, Sophie
    Sefrioui, David
    Emile, Jean-Francois
    Laurent-Puig, Pierre
    Bibeau, Frederic
    Michel, Pierre
    Sarafan-Vasseur, Nasrin
    Lepage, Come
    Di Fiore, Frederic
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Circulating tumor DNA and recurrence risk in stage II-III gastric cancer.
    Yuan, Shu-Qiang
    Huang, You-Sheng
    Nie, Run-Cong
    Chen, Yingbo
    Wang, Si-Yu
    Sun, Xiaowei
    Li, Yuanfang
    Liu, Ze-Kun
    Chen, Yan-Xing
    Yao, Yi-Chen
    Xu, Yu
    Qiu, Haibo
    Liang, Yao
    Wang, Wei
    Zhou, Zhiwei
    Xu, Rui-Hua
    Wang, Feng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Prognostic significance of pathological biomarkers in patients with stage II-III colorectal cancer
    Funaioli, C.
    Pinto, C.
    Ceccarelli, C.
    Di Fabio, F.
    Cuicchi, D.
    Llimpe, F. L. Rojas
    Lombardi, R.
    Longobardi, C.
    Bottazzi, M.
    Martoni, A. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
    Akagunduz, Baran
    Guven, Deniz Can
    Ozer, Muhammet
    Okten, Ilker Nihat
    Atag, Elif
    Unek, Ilkay Tugba
    Tatli, Ali Murat
    Karaoglu, Aziz
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)
  • [7] Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy
    Jacobs, S. A.
    Sethi, H.
    Kolveska, T.
    George, T. J.
    Shchegrova, S.
    Tin, T.
    Lee, J.
    Olson, A.
    Renner, D.
    Kalashnikova, E.
    Yothers, G.
    Wolmark, N.
    Pogue-Geile, K. L.
    Srinivasan, A.
    Kortmansky, J.
    Louie, M.
    Salari, R.
    Zimmermann, B.
    Aleshin, A.
    Allegra, C. J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Toward a circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients
    Soto, J. L.
    Garrigos, N.
    Gallego-Plazas, J.
    Guaraz, P.
    Garcia-Bautista, M.
    Castillejo, A.
    Gomez, A.
    Casado-Llavona, C.
    Rodriguez-Lescure, A.
    Carrato, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 187 - 187
  • [9] Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy
    Lin, Po-Han
    Wang, Ming-Yang
    Lo, Chiao
    Tsai, Li-Wei
    Yen, Tzu-Chun
    Huang, Thomas Yoyan
    Huang, Wei-Chih
    Yang, Karen
    Chen, Chih-Kai
    Fan, Sheng-Chih
    Kuo, Sung-Hsin
    Huang, Chiun-Sheng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients
    Hua, Xinwei
    Kratz, Mario
    Malen, Rachel C.
    Dai, James Y.
    Lindstrom, Sara
    Zheng, Yingye
    Newcomb, Polly A.
    [J]. BRITISH JOURNAL OF CANCER, 2021, 125 (06) : 806 - 815